In this video, Xiuning Le, MD, PhD, discusses how the definition of EGFR-mutated lung cancer has expanded in recent years.

Johnson & Johnson has filed its bispecific antibody amivantamab to the FDA, hoping to muscle into the big market for drugs that are used to treat EGFR-positive non-small cell lung cancer (NSCLC).

According to Nice, osimertinib can help stop cancer from returning after surgery by targeting cells that have EGFR mutations. The treatment was initially made available on the NHS through the Cancer ...

we are far from a consensus regarding the criteria for the use of anti-EGFR drugs. Unsatisfactory results in clinical trials invariably bring forth issues regarding lack of proper patient ...

Image: Adobe Stock. As part of a dedicated Workgroup for Implementation of Race-Free eGFR-Based Medication-Related Decisions, the NKF recommends researchers and providers switch from the Cockcroft ...

Tagrisso has been recommended as an adjuvant therapy following complete surgical resection in adults with stage 1B to 3A ...

That's important for AZ, as Tagrisso is starting to face the threat of competition from other EGFR drugs, including Johnson & Johnson's fast-growing EGFRxMET bispecific antibody Rybrevant ...

The molecular basis and mechanisms of action of combining classic cytotoxic agents (e.g. platinum-containing drugs, taxanes, etc.) and novel agents (e.g. tirapazamine, EGFR inhibitors and other ...

No randomized clinical trials have directly compared empagliflozin with dapagliflozin for type 2 diabetes, so investigators conducted a large comparative effectiveness study examining kidney outcomes.